Private equity giants Blackstone and TPG announced their plan to acquire Hologic, a leading medical diagnostics firm, for $18.3 billion including debt. This substantial transaction represents one of the largest Medtech Acquisitions in almost two decades. Hologic specializes in women’s health diagnostics, including critical breast and cervical cancer screening technologies. This buyout highlights a growing trend where private equity firms leverage access to easier financing, targeting undervalued sectors like healthcare in the United States.
Private equity firms Blackstone and TPG agreed to pay $76 per share in cash for all outstanding Hologic shares. This offer implies a nearly 6% premium to the stock’s last closing price. Shareholders will also receive a non-tradable contingent value right (CVR) of up to $3 per share. This CVR is payable if Hologic’s Breast Health business meets revenue targets in fiscal years 2026 and 2027, potentially bringing the total payout to $79 per share. Furthermore, five major banks – Citigroup Inc, Bank of America Corp, Barclays PLC, Royal Bank of Canada, and Sumitomo Mitsui Banking Corp – committed to provide the necessary debt financing for this substantial deal.
The Strategic Importance of Medtech Acquisitions
The acquisition reflects a broader trend in the healthcare sector. Private equity investment has become a significant force, driving consolidation and accelerating innovation within the medical device manufacturing ecosystem. Many experts view this as positive for the medtech sector. It expands the pool of acquirers, leading to stronger businesses that may re-emerge as public assets eventually. These firms aim to enhance operational efficiencies and unlock new growth channels through strategic mergers and acquisitions. Additionally, PE investment often provides critical capital for research and development, particularly for startups and scale-ups in life sciences, fostering the creation of new technologies.
Blackstone and TPG plan to accelerate Hologic’s research efforts, pursue further acquisitions, and develop new products. They also intend to operate the company without the constant pressure of quarterly earnings. Hologic’s products are well-regarded by clinicians and patients for their innovation and difficulty to replicate, giving the company strong market share and pricing power. This makes Hologic an attractive target for private equity, which often seeks companies with predictable revenue streams and growth potential.
The deal is expected to close in the first half of 2026, pending approval from Hologic’s stockholders and various regulatory bodies. Significant minority investments also come from a unit of the Abu Dhabi Investment Authority and an affiliate of GIC. Goldman Sachs advised Hologic on this transaction, while Citi provided counsel to the Blackstone-TPG consortium. Legal advisors included Wachtell, Lipton, Rosen & Katz for Hologic, and Kirkland & Ellis LLP and Ropes & Gray for the buyers.
Frequently Asked Questions
Q1: What is the total value of the Hologic acquisition?
The total value of the acquisition by Blackstone and TPG for Hologic is up to $18.3 billion, including debt. This includes a cash payment of $76 per share and a contingent value right (CVR) of up to $3 per share.
Q2: What is Hologic’s specialty?
Hologic is a medical diagnostics firm specializing in women’s health diagnostics. Its offerings include screening tools for breast and cervical cancer, among other critical medical technologies. For professionals interested in this area, a Obstetrics Gynecology And Womens Health Speciality Course could provide valuable insights.
Q3: When is the Hologic acquisition expected to close?
The acquisition of Hologic by Blackstone and TPG is anticipated to close in the first half of calendar year 2026, subject to stockholder and regulatory approvals.
References
- Blackstone, TPG to take medtech Hologic private for $18.3 billion – ETHealthworld
- Hologic to be acquired by private equity firms Blackstone, TPG for up to $18.3B. (2025, October 21).
- Hologic to be Acquired by Blackstone and TPG for up to $79 per Share. (2025, October 21).
- Blackstone and TPG poised for $17bn move on Hologic amid healthcare deal surge. (2025, October 20).
- The Impact of Private Equity Investment in MedTech – Mathias Synergy Solutions. (2025, July 17).
- Kirkland Advises Blackstone and TPG on up to $18.3 Billion Acquisition of Hologic | News. (2025, October 21).
- How private equity can drive innovation in the healthcare industry – Unicamillus. (2023, December 3).
- Private Equity is becoming increasingly important for MedTech Innovation – Picard Angst. (2022, August 29).
- Funding Innovation in Healthcare: The Good Case for Private Equity – EQT Group. (2024, July 30).
- PE seeks stakes in healthcare diagnostics sector: 5 deals. (2025, April 25).
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.